CellCarta

What CellCarta does

CellCarta is a global contract research organization providing precision medicine laboratory services to biopharmaceutical and biotechnology sponsors across all phases of drug development. The company operates an integrated multi-platform model spanning immune monitoring (flow cytometry, CyTOF, ELISpot), histopathology (multiplex IHC, immunofluorescence, digital pathology, spatial biology), proteomics (Immuno-MRM, mass spectrometry, Olink, MSD, Ella), and genomics (NGS, qPCR, dPCR, RNA-seq), supplemented by sample management, kitting, and biorepository logistics services. End customers are biopharmaceutical companies developing precision medicines, with a customer base that includes 17 of the top 20 pharma companies and more than 230 sponsors at the Lake Forest facility alone. The company is privately held by Arsenal Capital Partners, was formed through the 2019 merger of Caprion Biosciences and HistoGeneX, and has subsequently acquired Primity Bio, Serametrix, Clinical Logistics, Mosaic Laboratories, Reveal Biosciences, and Biogazelle, building nine facilities across Canada, the United States, Belgium, Australia, and China with more than 700 employees.

The company's revenue model is fee-for-service contract research, with project-based pricing negotiated by scope, complexity, and volume rather than publicly disclosed pricing. Distribution runs through direct enterprise sales to pharma sponsors and through strategic partnerships with Leica Biosystems (CDx co-development), Sonic Healthcare USA (CDx commercial lab), Pillar Biosciences (NGS tumor profiling), Lunit (AI pathology), Biofidelity (Aspyre Lung assay), Leinco Technologies (proteomics), Standard BioTools (CyTOF tooling), Slope (kit logistics), and RegASK (regulatory AI). Proprietary technology assets include the CellEngine cloud cytometry software, the Antigen Atlas database, Immuno-MRM assays, and the CDx Bridge Model, which combines a single-site PMA regulatory pathway with global lab network scalability for companion diagnostic commercialization. Operational certifications (CAP, CLIA, ISO 15189, ISO 13485, HGRAC, GDPR, CCPA) across multiple jurisdictions form the compliance backbone required for regulated clinical trial biomarker testing and CDx development under FDA and IVDR frameworks.

Name

CellCarta

Legal name

CellCarta Biosciences Inc.

Website

https://cellcarta.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

501–1,000 employees

Short description

CellCarta is a global CRO providing integrated precision medicine laboratory services — including immune monitoring, histopathology, proteomics, genomics, and companion diagnostic development — to biopharmaceutical sponsors across all phases of drug development, operating nine facilities across four continents with 700+ employees.

Ownership category

akta.pro rank

Product category

Contract Research Organization / Biomarker Laboratory Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Biomarker laboratory services
• Companion diagnostic development
• Contract research organization
• Proteomics and genomics
• Histopathology and digital pathology

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Contract Research Organization Laboratory Services: CellCarta generates revenue primarily through fee-for-service contracts with biopharmaceutical companies for biomarker testing services across immunology, histopathology, proteomics, and genomics. Services are provided on a project basis throughout the drug development cycle from discovery through late-stage clinical trials.
2. Companion Diagnostic Development and Testing: Revenue generated from CDx assay development, regulatory support, and clinical testing services, with potential for commercial kit planning and post-approval testing through the Lab Network model.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels9 records

Core offering

CellCarta is a global contract research organization providing precision medicine laboratory services to biopharmaceutical sponsors, integrating biomarker testing, immune monitoring, histopathology (including digital pathology), proteomics, genomics, companion diagnostic development, and sample logistics across nine CAP-accredited facilities. Services span the drug development cycle from discovery through late-stage clinical trials and include regulatory submission support for FDA and IVDR pathways, with a CDx Bridge Model that connects centralized single-site approval to a global Lab Network for commercial deployment.

Product overview

CellCarta is a global contract research organization (CRO) providing precision medicine laboratory services to the biopharmaceutical industry. The offering is organized as an integrated platform-plus-services model, combining four core technology platforms (Immunology/Immune Monitoring, Histopathology including Digital Pathology, Proteomics, and Genomics) with comprehensive biomarker services, companion diagnostic (CDx) development, sample management logistics, and regulatory expertise. The portfolio includes specialized technologies such as Ella™ (automated ELISA multiplexing), Olink™ PEA, Mass Cytometry (CyTOF), Mass Spectrometry, Nanostring™, Spatial Biology (including COMET™), and CellEngine® Software for cytometry analysis. CellCarta offers therapeutic expertise across oncology (including ADC solutions and cell therapy), immunology, infectious diseases, neurosciences, and targeted protein degraders. The CDx Bridge Model and Lab Network strategy enable end-to-end companion diagnostic commercialization from single-site approval to global deployment.

Differentiator

Problem solved

Functional benefit

Brands

• CellEngine: Comprehensive cloud-based cytometry analysis software developed by CellCarta for rapid analysis of large datasets
• Antigen Atlas
• Ella

Products and services

• Biomarker Solutions Comprehensive biomarker development and validation services supporting all phases of therapeutic development, including clinical biomarkers, discovery and preclinical services, and mass spectrometry-based biomarker services for biopharmaceutical sponsors.
• Immune Monitoring Services

Quantifiable outcome

• Move from project initiation to clinical trial readiness in approximately 5 months for FGFR NGS assay (RUO to IUO, validation, and regulatory submission support)
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and supporting.

• Leica Biosystems (Danaher)coreStrategic or Co-development Partner · 29 May 2026CellCarta and Leica Biosystems expanded their companion diagnostic (CDx) joint development model from China to global biopharma sponsors. The partnership integrates assay development, clinical trial execution, regulatory strategy, and commercial kit planning within a unified framework leveraging Leica's digital pathology capabilities (Aperio scanners, HALO/HALO Dx platforms) and AI-enabled ecosystem. The model enables parallel progression across CDx development stages, reduces duplicated work, and establishes a clear path to registration and commercialization globally.
• Sonic Healthcare USAcoreChannel Partner/ Reseller/ Distributor · 27 May 2026Sonic Healthcare USA became the first committed commercial laboratory partner in CellCarta's Lab Network strategy to commercialize companion diagnostics developed through CellCarta's single-site PMA CDx bridging model. CellCarta develops CDx assays, generates evidence packages, and performs testing; Sonic serves as the provider-facing laboratory partner enabling order flow, customer relationships, and market access execution across oncology, autoimmune disease, and precision medicine settings. The partnership bridges centralized single-site approval to broader commercial deployment.
• Standard BioToolssupportingTechnology or Integration · 26 May 2026Development partnership for the CyTOF Cleanup Tool built directly into CellEngine software. The tool automates preprocessing of CyTOF FCS files to identify live, single cells and generate QC reports in seconds, enabling users to move immediately to insights without manual intervention. Leverages CellEngine's fast clustering and dimensionality reduction algorithms and advanced visualizations.
• Leinco TechnologiessupportingTechnology or Integration · 23 April 2026Strategic collaboration to advance proteomics solutions for drug development in immuno-oncology and targeted therapeutic modalities. The partnership integrates Leinco's validated antibody portfolio for IHC and spatial biology platforms with CellCarta's Immuno-MRM assays and CPTAC antibody library. Combined offering aims to enhance sensitivity and specificity of proteomic analyses to accelerate biomarker discovery and support personalized medicine approaches.
• RegASKsupportingTechnology or Integration · 21 April 2026Year-long collaboration using RegASK's AI-driven regulatory intelligence platform to modernize CellCarta's regulatory affairs operations. Automated regulatory monitoring and intelligence generation, reducing research cycles that previously took up to 9 hours per week to near real-time delivery through a centralized regulatory intelligence hub. CellCarta plans to deepen AI adoption with agentic AI agents for content curation, impact assessment, and stakeholder collaboration.
• Pillar BiosciencescoreStrategic or Co-development Partner · 2 April 2026Multi-year global strategic partnership combining Pillar's oncoReveal kitted NGS panels (FGFR, Essential, Fusion) with CellCarta's global laboratory network and biomarker expertise to reduce screening friction, improve turnaround times, and support scalable companion diagnostic programs for biomarker-driven oncology trials. The partnership enables fit-for-purpose indication-specific panels and custom panel flexibility as assets advance. Jointly accelerated FGFR NGS assay from RUO to IUO for a global Phase 3 oncology trial in approximately 5 months.
• LunitcoreTechnology or Integration · 30 March 2026Strategic collaboration to integrate Lunit's platform-agnostic AI pathology algorithms with CellCarta's global CDx execution and regulated laboratory infrastructure for biopharmaceutical clients. The collaboration aims to provide faster, more cost-effective solutions for biomarker analysis and clinical trial testing through an integrated approach involving platform-agnostic AI deployment and LDT-based support strategies for global trials. Companies plan to begin with jointly selected pilot opportunities demonstrating combined capabilities across trial operations and AI image analysis, with expansion as additional use cases are validated.
• BiofidelitycoreTechnology or Integration · 19 March 2026CellCarta obtained exclusive global rights to offer Biofidelity's Aspyre Lung assay (pyrophosphorolysis-based lung cancer mutation detection test targeting 111 mutations in 11 genes relevant to NSCLC) in clinical trial settings, expanding a strategic partnership established the prior year. The deal positions CellCarta as the exclusive clinical trial partner for Aspyre Lung and establishes a coordinated framework for global deployment, with potential for future collaboration on Biofidelity's minimal residual disease technology.
• SlopesupportingTechnology or Integration · 3 February 2026Slope's Kit Inventory Portal (KIP) formalized as a standard component of CellCarta's logistics offering following a successful pilot. The platform enables clinical sites to place kit orders directly, with automated resupply capabilities and customizable approval workflows. Orders transmit directly to CellCarta's ERP system with shipment tracking syncing to site workspaces. The collaboration has demonstrated up to 71% reduction in lab kit waste, 98% site adoption on sponsor-contracted trials, and up to 98% fewer lab queries. Streamlines sample collection kit ordering, inventory management, and resupply workflows across new and existing client studies.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• NeoGenomics: US-based specialty CRO/laboratory providing oncology-focused biomarker testing, molecular diagnostics, and companion diagnostic development services to biopharma. Highly comparable to CellCarta given overlapping focus on oncology biomarker assays, CDx development, and pharma clinical trial services, though smaller and more oncology-concentrated.
• Q² Solutions (IQVIA/Quest joint venture): Specialized central and biomarker laboratory services provider for clinical trials, jointly owned by IQVIA and Quest Diagnostics. Directly comparable to CellCarta in biomarker assay development, genomic and flow cytometry services, and central lab support for pharma-sponsored trials.
• Medpace Holdings: Mid-sized full-service CRO with strong central laboratory and biomarker capabilities supporting biotech and pharma clinical trials. Comparable to CellCarta as a focused, mid-sized CRO competing for biomarker-driven trial work, though more weighted toward full clinical trial execution than specialty biomarker/CDx.

Broad incumbents

• IQVIA: World's largest CRO with R&D Solutions, Technology & Analytics, and laboratory services including Q² Solutions biomarker and central lab offerings to biopharma. Comparable as a buyer of biomarker and CDx services for biopharma trials, though IQVIA's scale and breadth make it a broad incumbent rather than a direct specialist competitor.
• Charles River Laboratories: Global CRO offering discovery, safety assessment, and integrated laboratory services including biomarker and cell therapy support to biopharma. Overlaps with CellCarta in biomarker assays and cell therapy capabilities but operates at significantly larger scale across a broader service portfolio.
• Labcorp (Fortrea): Fortrea is the post-spin clinical development and commercialization services business from Labcorp, a global full-service CRO with central laboratory, biomarker, and CDx capabilities serving the same biopharma client base as CellCarta. It is a much broader incumbent that competes on integrated trial execution rather than specialized biomarker depth.
• Eurofins Scientific: Global bioanalytical and clinical testing group offering biomarker, genomics, and CDx-related laboratory services through its pharma services and clinical diagnostics divisions. Comparable to CellCarta in biomarker and bioanalytical testing for pharma, but operates across a much broader portfolio of testing services and geographies.
• ICON plc: Global CRO providing clinical research, laboratory, and biomarker services (post-PRA Health and Symphony Health additions) to biopharma. Comparable to CellCarta in serving biopharma clinical trial needs, particularly in central lab and bioanalytical services, though with a broader CRO scope.

Others

• Bio-Techne: Developer and manufacturer of proteomics and genomics reagents, including the ProteinSimple, ExoDx, and R&D Systems brands used in biomarker and CDx workflows. Comparable as a technology enabler rather than a direct CRO competitor; Bio-Techne supplies reagents and platforms that CROs like CellCarta use, and overlaps in proteomics tools and services.

Emerging players

• Frontage Laboratories: US-based CRO providing bioanalytical, biomarker, CMC, and clinical trial laboratory services to biopharma with significant US-China operations. Comparable to CellCarta in integrated bioanalytical/biomarker lab services and a similar China footprint, though smaller and earlier in building global CDx and immune monitoring depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/CellCarta
• LinkedInlinkedin.com/company/cellcarta

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellCarta